Direct and indirect medical costs of bladder cancer in Iran

Cost Effectiveness and Resource Allocation

Research

Hamideh Rashidian¹  Kazem Zendehdel²  Rajabali Daroudi³  Mohammad Reza Ebadzadeh⁴  Ali Akbar Haghdoost⁵  Mehdi Raadabadi⁶ 

[1] Cancer Research Center, Cancer Institute of Iran, Imam Khomeini Hospital, Tehran University of Medical Sciences, PoBox: 13145-158, Keshavarz Bulvard, Tehran, Iran;Cancer Research Center, Cancer Institute of Iran, Imam Khomeini Hospital, Tehran University of Medical Sciences, PoBox: 13145-158, Keshavarz Bulvard, Tehran, Iran;Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran;Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran;Department of Urology, Bahonar Hospital, Kerman University of Medical Sciences, Kerman, Iran;HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran;Health Policy and Management Research Center, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran;

关键词: Economic burden;    Bladder cancer;    Prevalence;    Occurrence;    Iran;   

DOI  :  10.1186/s12962-023-00416-0

 received in 2022-08-15, accepted in 2023-01-03,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundBladder cancer is one of the most prevalent and costly cancers in the world. Estimating the economic burden of bladder cancer is essential for allocating resources to different sectors of health systems and determining the appropriate payment mechanisms. The present study aimed at estimating the economic burden of bladder cancer in Iran.MethodsIn this study, we used a prevalence-based approach for estimating the economic burden of bladder cancer. Direct and indirect costs of bladder cancer were calculated using the cost of illness and human capital approaches. Data were collected using a researcher-made checklist obtained from several sources including Iran bladder cancer clinical practice guideline, the Statistical Center of Iran, Iran’s Ministry of Cooperatives, Labor, and Social Welfare, Relative Value of Health Services (RVHS) book and Iranian Food and Drug Administration organization.The analyses were done by Microsoft Excel 2013 and Stata 13.ResultsThe number of the cases of 5-year prevalence of bladder cancer in Iran was estimated as 21,807 people in 2018. The economic burden of bladder cancer in Iran was estimated at US$ 86,695,474. Indirect medical costs constituted about two-third of the economic burden of bladder cancer, and mostly related to productivity loss due to mortality. Most of the direct medical costs (29.7%) were related to the stage T2–T3 and transurethral resection of bladder (31.01%) and radical cystectomy (19.99%) procedures.ConclusionOur results showed that the costs of bladder cancer, imposed on the healthcare system, were significant and mostly related to lost production costs. The implementation of screening and diagnostic programs can improve the survival rate and quality of life of patients and reduce the cost of lost productivity due to mortality in these patients.

【 授权许可】

CC BY   
© The Author(s) 2023